# US 2010/0168431 A1 · Novel isoquinolinium compounds useful in the preparation of cisatracurium and associated intermediates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168431 A1
- Document ID: US20100168431A1
- Status: Published application
- Kind: A1
- Application number: 12/598,378
- Filed: 2008-05-01
- Published: 2010-07-01
- Earliest claimed: 2007-05-01
- Assignees: Chemagis Ltd.
- Inventors: Vladimir Naddaka; Shen Jingshan; Oded Arad; Guo Hongli; Ofer Sharon; Eyal Klopfer; Shady Saeed
- Web page: https://patentgrep.com/patent/US20100168431A1

## CPC

- C07D 217/10: Quaternary compounds
- C07D 217/04: with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention provides novel isoquinolinium compounds, methods of producing the isoquinolinium compounds, and methods for converting them into cisatracurium, e.g., cisatracurium besylate. The isoquinolinium compounds of the present invention can be obtained in the form of solids, which can be purified using simple techniques and can be used to afford pure cisatracurium besylate without HPLC purification

## Claims

### Claim 1

A compound having the structural formula (VIII)
wherein X− is an anion selected from chloride, bromide, iodide, tetrafluoroborate, sulfate, hydrogensulfate, methanesulfonate, benzenesulfonate, p-toluenesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, oxalate, and tartrate, and Y is OR1 or NR2R3, R1, R2 and R3 are the same or different and each is independently selected from hydrogen, alkyl, aryl, and heteroaryl with the proviso that Y is not OH.

### Claim 2 (depends on 1)

The compound of claim 1 in substantially crystalline form, wherein X1 is benzenesulfonate (besylate) or iodide.

### Claim 3 (depends on 2)

The compound of claim 2, which is:
(1R-cis)-1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-2-tert-butoxycarbonylethyl-isoquinolinium iodide,
(1R-cis)-1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-2-tert-butoxycarbonylethyl-isoquinolinium besylate,
(1R-cis)-1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-2-aminocarbonylethyl-isoquinolinium iodide,
(1R-cis)-1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-2-methoxycarbonylethyl-isoquinolinium iodide, or
(1R-cis)-1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-2-benzyloxycarbonylethyl-isoquinolinium besylate.

### Claim 4 (depends on 3)

The compound of claim 3, which is a crystalline form of (1R-cis)-1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-2-tert-butoxycarbonylethyl-isoquinolinium besylate characterized by an X-ray powder diffraction pattern exhibiting strong diffraction peaks at 7.2, 10.6, 11.8, 14.2, 15.8, 17.1, 18.6, 21.0, 23.6, 25.3 and 28.2±0.2 degrees 2θ.

### Claim 5 (depends on 3)

The compound of claim 3, which is a crystalline form of (1R-cis)-1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-2-aminocarbonylethyl-isoquinolinium iodide characterized by an X-ray powder diffraction pattern exhibiting strong diffraction peaks at 4.8, 17.8, 18.3, 21.1, 24.5 and 25.8±0.2 degrees 2θ.

### Claim 6 (depends on 3)

The compound of claim 3, which is a crystalline form of (1R-cis)-1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-2-benzyloxycarbonylethyl-isoquinolinium besylate characterized by an X-ray powder diffraction pattern exhibiting strong diffraction peaks at 6.3, 11.5, 13.0, 13.3, 13.7, 15.9, 16.7, 18.9, 19.4, 20.0, 20.3, 21.3, 22.6, 23.1, 24.0 and 24.7±0.2 degrees 2θ.

### Claim 7 (depends on 3)

The compound of claim 3 having a purity greater than 98%.

### Claim 8 (depends on 7)

The compound of claim 7 having a purity greater than 99%.

### Claim 9

A compound having the structural formula (X)
and acid addition salts thereof, wherein Y is OR1 or NR2R3, wherein R1 is alkyl, aryl or heteroaryl, and R2 and R3 are the same or different and each is independently hydrogen, alkyl, aryl or heteroaryl, with the proviso that Y is not OH, or an acid addition salt thereof (IX).

### Claim 10 (depends on 9)

The compound of claim 9 in the form of an acid addition salt (IX), in substantially crystalline form, which is:
(1R)-1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-tert-butoxycarbonylethyl-isoquinoline oxalate,
(1R)-1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-aminocarbonylethyl-isoquinoline oxalate,
(1R)-1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methoxycarbonylethyl-isoquinolinium oxalate,
(1R)-1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-benzyloxycarbonylethyl-isoquinolinium oxalate, or
(1R)-1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-tert-butylaminocarbonylethyl-isoquinolinium oxalate.

### Claim 11 (depends on 9)

The compound of claim 9, which is a crystalline form of (1R)-1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-tert-butoxycarbonylethyl-isoquinolinium oxalate characterized by an X-ray powder diffraction pattern exhibiting strong diffraction peaks at 7.8, 11.3, 14.7, 16.7, 17.5, 19.3, 22.0, 23.1, 23.4 and 25.4±0.2 degrees 2θ.

### Claim 12 (depends on 9)

The compound of claim 9, which is a crystalline form of (1R)-1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-aminocarbonylethyl-isoquinolinium oxalate characterized by an X-ray powder diffraction pattern exhibiting strong diffraction peaks at 7.8, 10.2, 17.4, 21.5, 23.5, 25.5 and 27.1±0.2 degrees 2θ.

### Claim 13 (depends on 9)

The compound of claim 9, which is a crystalline form of (1R)-1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-benzyloxycarbonylethyl-isoquinolinium oxalate characterized by an X-ray powder diffraction pattern exhibiting strong diffraction peaks at 5.2, 7.8, 14.0, 17.3, 17.6 and 23.5±0.2 degrees 2θ.

### Claim 14 (depends on 9)

The compound of claim 9, which is a crystalline form of (1R)-1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-tert-butylaminocarbonylethyl-isoquinolinium oxalate characterized by an X-ray powder diffraction pattern exhibiting strong diffraction peaks at 5.4, 6.9, 12.6, 15.8, 17.8, 19.3, 26.2 and 26.8±0.2 degrees 2θ.

### Claim 15

A crystalline compound of the formula:
wherein X− is an anion selected from chloride, bromide, iodide, methanesulfonate, benzenesulfonate, p-toluenesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, tetrafluoroborate, oxalate, and tartarate.

### Claim 16 (depends on 15)

The crystalline compound of claim 15, wherein X− is selected from benzenesulfonate, iodide and tetrafluoroborate.

### Claim 17

A method for preparing cisatracurium, the method comprising converting a compound of the formula
into cisatracurium by coupling it with 1,5-pentanediol to produce the cisatracurium.

### Claim 18 (depends on 17)

The method of claim 17, wherein the cisatracurium is cisatracurium besylate.
